Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
about
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-UpEffectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed ViremiaHepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic StudyInflammation, Immune Activation, and Antiretroviral Therapy in HIVSwitch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialEfficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensModifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyOff-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter studyAntiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelA Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Switch strategies in antiretroviral therapy regimens.Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.Switching antiretroviral regimes for the treatment of HIV: safety implications.Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD).A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
P2860
Q28546894-2F9B3894-FA28-4F5F-BB03-8866C3759000Q28548630-4FC03F28-656A-49BB-B7BD-594ADDC2A833Q28552246-E2082CDB-876A-4DCE-B5C3-364F22E3BEA7Q33912595-90A49160-D09B-4863-92B7-B86BA62319EAQ35628276-1BFB5696-6C85-4D5B-AF8D-D7F7E6DD2001Q35652019-7C985BB2-1E1C-4CF4-9F3B-9A1983400C95Q35907952-83D3D6F4-8B03-4F02-9FB0-D7089D14FDFFQ36206941-C7ECF0B0-1525-49E6-BEA0-7937C46B02EEQ36426953-3AD4D676-03B4-4202-81CE-E9832C5E5321Q36628396-AE4FCCC9-B592-4DBC-8338-47D8AE084396Q37205614-4E5CD8BA-E815-4168-8EE4-6378A35302CFQ37234729-FCE427FB-BC92-4BC4-A6FF-F36429F99E91Q37305526-AA7C715F-AAB3-4C89-B56C-83BBCACD249DQ37538683-514DB479-921C-4540-9301-DB8BDD12ABC2Q38235295-5D4722EE-424E-4B25-8D3A-EEC46186C13EQ38263470-28346AC6-C9D1-469C-AD82-BC6FC7843626Q38379391-D253FCFA-088F-4319-9CCC-26D7A1E9FBCCQ38380110-0995F3D3-5B69-4579-94A2-062C6E1899DCQ38723259-4A6B35CB-7323-4DC9-87D5-5F6A32E45617Q38879406-C9E9B91D-EB32-4FB1-BF68-54C5A1E8D5A0Q39519582-3F4929E7-0933-40C4-86C7-6C0CD6DD158DQ39760086-A0B27B78-B3E0-47D7-B3B5-3C7F48EB895CQ39980493-C8380C3A-FBCD-4187-9EF3-F60B53C71E86Q40100018-AAEB1ABC-0419-4C2E-AA36-2AE9ECEA21F4Q40116904-F2B56197-6D26-42DF-8046-419B0072F1CAQ40132756-2EB433AF-CB6B-48CD-A151-684B9E1E82FAQ40145206-AF332052-924B-404A-8861-7FC4D1F5D83EQ40401616-472826C3-4F87-4A3D-AEED-62084D2323A1Q40751471-B43D653A-5328-448F-B9AC-D05186CD6765Q40790663-92B33DC1-FD20-4996-B305-E19745932F5FQ40799305-7A901A3F-D570-4AFD-B8DB-D085C951CA7CQ41428068-01A15AD7-42B2-4E26-A705-A0FACE1EE2C1Q42199901-23BEEF37-D77A-4414-B408-2E5549042444Q42219119-CE2396C2-0718-4EFF-8545-41B17C927F88Q47145824-61DDE09A-C1EB-43D1-B2E0-12D006C22E71Q47164735-7E3AAABE-FAEF-4DA8-A205-A22146C1255EQ47305467-59198133-DFFB-40C6-A634-DDB6E0A3A0FAQ47321307-456F4BEA-4C9E-4079-B767-CFA0FC1C2CA7Q47553402-A0001867-2563-46FD-A520-A22BF6C204B6Q47800071-1273AAC7-C5FD-458B-98A7-F96CE5EB43C5
P2860
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@en
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@nl
type
label
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@en
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@nl
prefLabel
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@en
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@nl
P2093
P1433
P1476
Simplification to rilpivirine/ ...... 1 RNA-suppressed participants.
@en
P2093
Brian Gazzard
David Shamblaw
Elizabeth Elbert
Frank J Palella
Jan Van Lunzen
Jason Flamm
Jason Hindman
Kirsten White
Martin Fisher
Peter Ruane
P304
P356
10.1097/QAD.0000000000000087
P407
P577
2014-01-01T00:00:00Z